Life sciences firm Danaher beats Q3 revenue estimates

Overview

• Danaher Q3 revenue up 4.5% yr/yr to $6.1 bln, beating analysts' expectations

• Adjusted EPS for Q3 at $1.89, exceeding expectations

• Company attributes growth to bioprocessing and higher-than-expected respiratory revenue at Cepheid

Outlook

• Danaher maintains full-year adjusted EPS guidance of $7.70 to $7.80

• Company expects low-single digit core revenue growth for 2025

• Danaher anticipates 2.5% sales increase from currency impact in Q4 2025

Result Drivers

• BIOPROCESSING MOMENTUM - Co cites strong performance in bioprocessing as a key driver of Q3 results

• RESPIRATORY REVENUE - Higher-than-expected respiratory revenue at Cepheid contributed to exceeding expectations

• DBS EXECUTION - Co attributes exceeding expectations to DBS-driven execution

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Danaher Corp is $240.00, about 13.2% above its October 20 closing price of $208.39

• The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nPn1V157qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.